Nadine Abi-Jaoudeh

Appearances

OUTCOMES BY KEY PROGNOSTIC FACTORS IN EMERALD-1: A PHASE 3 STUDY OF DURVALUMAB ± BEVACIZUMAB WITH TRANSARTERIAL CHEMOEMBOLIZATION (TACE) IN PARTICIPANTS WITH EMBOLIZATION-ELIGIBLE UNRESECTABLE HEPATOCELLULAR CARCINOMA (UHCC)
Date
May 4, 2025
Speaker
Nadine Abi-Jaoudeh